Third-quarter sales of $2.98 billion increased 5% on both a reported and organic basis,1, 2 reflecting growth in all segments and divisions
Third-quarter U.S. GAAP3 diluted earnings per share (EPS) of $0.57;
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in
Explores how healthcare organizations can maximize the impact of technology investments
Introduces a four-stage technology maturity framework to help hospitals benchmark progress and identify areas to
Global medtech CFO with broad transformation and leadership experience to help advance Baxter’s turnaround, financial discipline and value creation
Baxter International Inc. (NYSE:BAX), a global medtech leader, today
Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the pricing terms for its previously announced cash tender offers (each, an "Offer" and collectively, the
Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early results of its previously announced cash tender offers (each, an "Offer" and collectively, the
Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has commenced cash tender offers (each, an "Offer" and collectively, the "Offers") for the
Second-quarter sales of $2.96 billion increased 5% on both a reported and organic basis,1, 2 reflecting growth in all segments and divisions
Second-quarter U.S. GAAP3 diluted earnings per share (EPS) of $0.26;
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To
Announces new targets, including Net-Zero greenhouse gas emissions (GHG) across Scope 1 and Scope 2 by 2050 and 100% renewable electricity by 2040
Introduces company’s refreshed sustainability strategy, goals and
Multi-year exclusive agreement to expand access to next-generation 3D surgical visualization worldwideSEOUL, South Korea, June 18, 2026 /PRNewswire/ -- MediThinQ, a South Korea-based innovator in surgical visualization
Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D
Sales from continuing operations of $2.7 billion increased 3% on a reported basis and declined 1% on an organic basis1,2
U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.03);
Highlights include the AAT XR, the next-generation version of the Allen Advance Table designed to support surgical teams across a range of spine procedures, and the Dynamo Series smart stretcher
Baxter International
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To
